कंपनी का अवलोकन
Moleculin Biotech, Inc. (MBRX) operates as a late-stage pharmaceutical development company dedicated to the creation of therapeutic candidates designed for the treatment of tumors and viruses. The enterprise functions within the Healthcare sector, specifically inside the Biotechnology industry, where the focus is on advancing scientific research toward clinical applications for serious medical conditions. The company currently employs a workforce of 17 individuals, supporting its operational and developmental activities. With a market capitalization of $13.61M, the firm holds a relatively small position in the biotechnology market, a status that is further characterized by the absence of reported annual revenue in the available financial data.
वित्तीय स्वास्थ्य
The company reported a net income of $-33,664,000 for the trailing twelve months, while its EBITDA stands at $-25,013,000, indicating a significant negative earnings environment typical of early to mid-stage development entities. Although specific revenue figures are not disclosed in the current data, the substantial gap between the reported revenue status and the net loss reveals a cost structure dominated by research and development expenditures rather than operational profitability. The firm generated a free cash flow of $-12,261,375, which signifies a high consumption of cash reserves needed to fund ongoing clinical trials and drug development processes without generating operational cash inflows. Analysis of the three margin metrics shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, collectively indicating that the company has not yet achieved profitability at the gross or operational level. In terms of liquidity, the company holds $8.88M in cash against a debt level of $359,000, resulting in a debt-to-equity ratio of 2.39, which suggests a leveraged balance sheet structure despite the low absolute debt amount. The current ratio is recorded at 1.41, suggesting that the company maintains sufficient current assets to cover its short-term liabilities with a buffer of roughly 41%. Return on Equity is reported at -256.0% and Return on Assets at -80.4%, metrics that reveal management has not yet generated positive returns on the capital invested or assets accumulated, a common challenge for biotechnology firms in the pre-commercialization phase.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A due to the absence of positive earnings, while the forward P/E is recorded as -0.02, reflecting the expectation of continued negative earnings in the near term rather than a traditional earnings trajectory. The price-to-book ratio is 0.54, which indicates that the market values the company at less than its book value, suggesting a potential discount often seen in speculative biotechnology stocks with uncertain future commercial potential. Since revenue is not available, the price-to-sales ratio is N/A, and the EV/EBITDA stands at -0.20, both of which are alternative valuation metrics that currently highlight the negative earnings multiple rather than traditional revenue-based valuation. The stock has traded between a 52-week high of $28.60 and a 52-week low of $1.79, illustrating extreme volatility and a wide trading range that encompasses significant price discovery. The beta value is 1.67, which implies that the stock price is expected to be more volatile than the broader market, moving with greater intensity than the general equity indices.
Growth & Income
Revenue growth year-over-year is listed as N/A and earnings growth year-over-year is also N/A, meaning that historical growth rates cannot be calculated from the current financial statements to determine if earnings are growing faster or slower than revenue. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm does not distribute cash to shareholders but instead retains all available resources. This non-dividend status confirms that the company reinvests its limited financial capital directly into the development of its lead drug candidate, Annamycin, and other therapeutic programs rather than providing income to investors. Consequently, the overall growth and income profile of Moleculin Biotech, Inc. is characterized by a total reliance on future clinical success and capital raising efforts to drive value, offering no current income stream to compensate for the high financial risk and negative returns on equity.